Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

Full DD Report for BVXV

You must become a subscriber to view this report.


Recent News from (NASDAQ: BVXV)

BiondVax Announces Fourth Quarter and Full Year 2017 Financial Results and Update
NESS ZIONA, Israel , April 30, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced its fourth quarter and full year financia...
Source: PR Newswire
Date: April, 30 2018 16:05
FDA accepts Sanofi Pasteur's marketing application for expanded use of flu vaccine
The FDA accepts for review Sanofi Pasteur's ( SNY +0.6% ) supplemental marketing application seeking approval to use the 0.5 mL dose of Fluzone Quadrivalent (influenza vaccine) in children ages six months to 35 months. It is is currently approved for use in kids at least 36 months of age...
Source: SeekingAlpha
Date: April, 25 2018 09:45
Key events next week - healthcare
Noteworthy events during the week of April 15 - 21 for healthcare investors. More news on: Bristol-Myers Squibb Company, Biondvax Pharmaceuticals, Rigel Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: April, 13 2018 09:56
Blog Exposure - BiondVax Pharma Initiated NIH-Sponsored Phase-2 Clinical Trial of M-001 in the US
Stock Monitor: Dare Bioscience Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 13, 2018 / Active-Investors.com has just released a free research report on BiondVax Pharma Ltd (NASDAQ: BVXV ) (''BiondVax''). If you want access to this report all you need to do is sign up now by...
Source: ACCESSWIRE IA
Date: April, 13 2018 07:20
BiondVax to Present at Universal Influenza Vaccines Conference
NESS ZIONA, Israel , April 12, 2018 /PRNewswire/ --  BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the universal flu vaccine candidate M-001, reported today it will present at the Universal Influenza Vaccines 2018 Conference. The conference is being held on April ...
Source: PR Newswire
Date: April, 12 2018 06:30
BiondVax up 3% on start of mid-stage study of flu vaccine M-001
Thinly traded BiondVax ( BVXV +3.4% ) is up on modestly higher volume, albeit on turnover of only 15.5K shares, on the heels of its announcement that enrollment is underway in an NIAID-sponsored Phase 2 clinical trial evaluating universal flu vaccine candidate M-001. More news on: Bion...
Source: SeekingAlpha
Date: April, 11 2018 12:07
BiondVax Begins NIH-Sponsored Phase 2 Clinical Trial of Its Universal Flu Vaccine in the United States
NESS ZIONA, Israel , April 11, 2018 /PRNewswire/ --   BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) reported today the first participant enrollment in the United States in a Phase 2 clinical trial of the company's universal flu vaccine candidate, M-001. The trial is sponsored by ...
Source: PR Newswire
Date: April, 11 2018 07:45
Recent Analysis Shows Norbord, BiondVax Pharmaceuticals, NXP Semiconductors N.V, Lazard, Canadian Solar, and Sierra Wireless Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, April 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Norbord Inc. (NYSE:OSB), BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), NX...
Source: GlobeNewswire
Date: April, 09 2018 08:15
Recent Analysis Shows KB Financial Group, Southern Missouri, Net 1 UEPS Technologies, Financial Engines, Carbonite, and BiondVax Pharmaceuticals Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of KB Financial Group Inc (NYSE:KB), Southern Missouri Bancorp, Inc. (NASDA...
Source: GlobeNewswire
Date: March, 15 2018 08:25
BiondVax Appoints CRO to Conduct Pivotal Clinical Efficacy Phase 3 Trial of Its Novel Universal Flu Vaccine Candidate
NESS ZIONA, Israel , March 13, 2018 /PRNewswire/ --  BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the Universal Flu Vaccine candidate M-001, announced today the signing of a Master Service Agreement (MSA) with a contract research organization (CRO) to conduct the fi...
Source: PR Newswire
Date: March, 13 2018 09:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-175.605.69995.705.605,352
2018-08-165.745.53015.745.51746,365
2018-08-155.755.785.855.5011,598
2018-08-145.805.895.925.804,372
2018-08-135.905.866.025.7012,061

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-171,3912,69151.6908Short
2018-08-168401,64051.2195Short
2018-08-151,4691,51497.0277Short
2018-08-147991,46454.5765Short
2018-08-131,4501,65087.8788Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BVXV.


About BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

Logo for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: BVXV)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 01 2018
      Annual and transition report of foreign private issuers under sections 13 or 15(d)
      Filing Type: 20-FFiling Source: edgar
      Filing Date: April, 30 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 18 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 29 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 21 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 14 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: February, 22 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: February, 22 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 02 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: January, 24 2018

       

       


      Daily Technical Chart for (NASDAQ: BVXV)

      Daily Technical Chart for (NASDAQ: BVXV)


      Stay tuned for daily updates and more on (NASDAQ: BVXV)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: BVXV)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BVXV is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of BVXV and does not buy, sell, or trade any shares of BVXV. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/